Do you plan to offer adjuvant olaparib to all gBRCA+ breast cancer whether TNBC or HR+?

In subset analyses of OlympiA there seems to be smaller magnitude of benefit among HR+ patients. In your opinion, should adjuvant olabarib be offered to all patients regardless of HR status or reserved for higher risk TNBC population?

Community PollStarted

Do you plan to offer adjuvant olaparib to all eligible BRCA+ breast cancer whether TNBC or HR+?

51 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers

Mednet MemberInvited Expert

Medical Oncology · Huntsman Cancer Institute at the University of Utah

Answered on

I offer adjuvant olaparib to germline BRCA mutated breast cancer patients (TNBC or hormone receptor positive and Her-2 negative) only if they meet the inclusion criteria that was used in the OlympiA study, which is as follows:

1) Patients with triple-negative breast cancer who were treated with adjuv...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert

Medical Oncology · Columbia University Medical Center

Answered on

I plan to offer adjuvant olaparib to all high risk gBRCA+ breast cancer given the benefit demonstrated in the ITT population of the OlympiA trial. These cancers are driven by the gBRCA mutation and there is no evidence that olaparib was less effective in HR+ patients. The subgroup analysis at median...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert

Medical Oncology · University of Texas MD Anderson Cancer Center

Answered on

Currently, the data support treating all germline BRCA positive patients that are high risk (TNBC or HR+) with Olaparib in the adjuvant setting.

Join for free or sign in to see the full answer